Only in French: Lettre ouverte – Rédigée par Mme Marie-Pierre Ippersiel, présidente et directrice générale, PRIMA Québec, et co-signée par les Directeurs généraux des RSRI * In its November 30 economic update, the Government of Canada announced $250 million over five years, starting next year, to support companies in innovation to stimulate growth and job…
Montréal (Quebec), November 19, 2020 — The prize rewards VLPExpressTM, a plant-based vaccine discovery platform developed by Medicago in collaboration with McGill and Laval universities. The project was funded in 2009 by CQDM with contributions from Pfizer, Merck, the Ministère de l’Économie et de l’Innovation, and the Business-Led Networks of Centres of Excellence program from…
Montreal – November 11 2020 – CQDM congratulates Mesentech on securing additional investment to support the clinical development of their bone-targeting drug candidate MES-1007, a drug with the potential to reverse bone wastage in Duchenne Muscular Dystrophy and other skeletal fragility diseases in pediatrics. Link to Mesentech’s Press Release: click here. “CQDM’s investment enabled Mesentech…
Dr. Christian Dansereau – Dr. Jean-Claude Tardif – Dr. Fouzia Laghrissi-Thode A collaboration between Perceiv AI, DalCor Pharmaceuticals and the Montreal Heart Institute Montreal (Quebec), November 5, 2020 — The CQDM is pleased to announce the launch of a $600,000 collaborative project in biopharma and artificial intelligence (AI) to develop an AI-driven precision medicine tool.…
Montreal, October 5th, 2020 – Richard Fajzel, Chairman of CQDM’s Board of Directors and Diane Gosselin, President and CEO of CQDM are pleased to announce the appointment of Philip Tagari to the Board of Directors. Philip Tagari is currently Vice President of Research (Therapeutic Discovery) at Amgen Inc., one of the world’s leading biotechnology companies.…
Dr Yves Fradet / Dr Frédéric Pouliot CQDM Awards a Grant to Centre de Recherche du CHU de Québec-Université Laval for a Study Collaboration With Merck Canada to Identify Biomarkers of Response to Pembrolizumab in Patients with Localized but Aggressive Prostate Cancer Montreal, July 20, 2020 – CQDM is pleased to announce a grant for…
Milad Dagher / David Juncker July 16, 2020 (Montreal, Quebec) – McGill University and CQDM announced today that a collaborative project between McGill and nplex biosciences to further develop a highly-scalable protein detection method, termed the “nELISA”, has been selected for funding by CQDM. The research team will receive a $1,000,000 grant for one year…
Montréal (Québec), July 14, 2020 – The biopharmaceutical research consortium CQDM is pleased to announce the launch of a project valued at over $300,000 to support the development of a molecular test designed to assess, among others, the risk of death in COVID-19 patients. The initiative proposed by MRM Proteomics Inc. is made possible with…
Montreal, June 22, 2020. CQDM is pleased to announce an investment in Mesentech Inc., an emerging biotech based in Vancouver, British Columbia, developing a bone-targeting technology platform to deliver drugs selectively to bone-tissue. The lead program, MES-1007, aims to restore bone density and strength in conditions such as osteogenesis imperfecta (brittle bone disease), congenital muscular…
Open letter – Published in the Hill Times (Ottawa) June 29th 2020 (https://www.hilltimes.com/2020/06/29/health-innovation-investing-now-to-face-the-crises-of-tomorrow/254763) & Published on LaPresse website June 20th 2020 (https://www.lapresse.ca/debats/opinions/2020-06-20/innovation-en-sante-investissons-maintenant-pour-faire-face-aux-crises-de-demain) Health innovation will play a key part in the battle against the devastating effects of the COVID-19 pandemic. As we have been doing since the beginning of the crisis, the leaders of the…